I. Monnet

13.7k total citations · 2 hit papers
286 papers, 7.0k citations indexed

About

I. Monnet is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Materials Chemistry. According to data from OpenAlex, I. Monnet has authored 286 papers receiving a total of 7.0k indexed citations (citations by other indexed papers that have themselves been cited), including 133 papers in Pulmonary and Respiratory Medicine, 106 papers in Oncology and 84 papers in Materials Chemistry. Recurrent topics in I. Monnet's work include Lung Cancer Treatments and Mutations (88 papers), Ion-surface interactions and analysis (58 papers) and Lung Cancer Research Studies (57 papers). I. Monnet is often cited by papers focused on Lung Cancer Treatments and Mutations (88 papers), Ion-surface interactions and analysis (58 papers) and Lung Cancer Research Studies (57 papers). I. Monnet collaborates with scholars based in France, United States and United Kingdom. I. Monnet's co-authors include C. Chouaïd, L. Thomé, C. Grygiel, Marie Wislez, G. Sattonnay, Jean-Luc Béchade, C. Legros, Fabrice Barlési, Marion Le Flem and Martine Antoine and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Environmental Science & Technology.

In The Last Decade

I. Monnet

278 papers receiving 6.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC

2021 201 citations Radj Gervais, I. Monnet et al. profile →
First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743

2022 158 citations Solange Peters, Arnaud Scherpereel et al. Annals of Oncology profile →

Peers

Countries citing papers authored by I. Monnet

Since Specialization

Citations

This map shows the geographic impact of I. Monnet's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by I. Monnet with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites I. Monnet more than expected).

Fields of papers citing papers by I. Monnet

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by I. Monnet. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by I. Monnet. The network helps show where I. Monnet may publish in the future.

Co-authorship network of co-authors of I. Monnet

This figure shows the co-authorship network connecting the top 25 collaborators of I. Monnet. A scholar is included among the top collaborators of I. Monnet based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with I. Monnet. I. Monnet is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Successive next-generation sequencing strategy for optimal fusion gene detection in non-small-cell lung cancer in clinical practice 2024 ·Pathology ·Simon Garinet, Audrey Lupo, Thomas Denize, (unknown), (unknown), (unknown), Elizabeth Fabre, (unknown), Laure Gibault, Etienne Giroux‐Leprieur, Boris Duchemann, I. Monnet, (unknown), Mihaela Aldea, (unknown), (unknown), Karen Leroy, Marie Wislez, Hélène Blons	2
2	Localised corrosion of iron and steel in the Callovo-Oxfordian porewater after 3 months at 120 °C: Characterizations at micro and nanoscale and formation mechanisms 2023 ·Corrosion Science ·(unknown), Delphine Neff, Florence Mercier‐Bion, Christian Bataillon, Philippe Dillmann, Emmanuel Gardès, I. Monnet, James J. Dynes, Eddy Foy	3
3	1359P Relationship between tumor TP53 gene mutation, circulating anti-p53 antibodies and response to first-line osimertinib in EGFR-mutated NSCLC patients 2023 ·Annals of Oncology ·Marc G. Denis, (unknown), Christine Sagan, (unknown), Audrey Vallée, Jacques Cadranel, Clarisse Audigier-Valette, Pascale Tomasini, Philippe Masson, (unknown), (unknown), Nicolas Girard, Alexis B. Cortot, (unknown), I. Monnet, M. Marcq, T. Urban, (unknown), H. Léna, Jaafar Bennouna	1
4	2179P Prospective monitoring of autoimmune events in cancer immunotherapy patients: A report on the first 658 patients in the PRAISE study 2023 ·Annals of Oncology ·E. Sebbag, Nicolas Cloarec, I. Monnet, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), C. Chouaïd, (unknown), (unknown)	1
5	Safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination in stage IV non-small-cell lung cancer: An open-label phase II trial (VinMetAtezo) 2023 ·Lung Cancer ·A. Vergnenègre, I. Monnet, Charles Ricordel, (unknown), (unknown), Massimo Bernardi, R. Corre, Florian Guisier, S. Hominal, G. Le Garff, Olivier Bylicki, Chrystèle Locher, Margaux Geier, C. Chouaïd, G. Robinet	5
6	Damage in InGaN/GaN bilayers upon Xe and Pb swift heavy ion irradiation 2022 ·Physical Chemistry Chemical Physics ·(unknown), (unknown), (unknown), M. R. Correia, Margaret Sequeira, S. Magalhães, (unknown), C. Grygiel, I. Monnet, (unknown), Christian Wetzel, E. Alves, K. Lorenz	5
7	Immune-Checkpoint Inhibitors for Malignant Pleural Mesothelioma: A French, Multicenter, Retrospective Real-World Study 2022 ·Cancers ·Jean‐Baptiste Assié, (unknown), Emmanuel Grolleau, Anthony Canellas, Margaux Geier, (unknown), (unknown), Aldo Renault, Pierre-Alexandre Hauss, (unknown), (unknown), Alexis B. Cortot, Marie Wislez, Clément Gauvain, C. Chouaïd, Arnaud Scherpereel, I. Monnet	11
8	Unravelling the secrets of the resistance of GaN to strongly ionising radiation 2021 ·Communications Physics ·Margaret Sequeira, (unknown), (unknown), Flyura Djurabekova, K. Nordlund, I. Monnet, Pablo Mota‐Santiago, P. Kluth, C. Grygiel, Shuo Zhang, E. Alves, K. Lorenz	40
9	The fate of Si and Fe while nuclear glass alters with steel and clay 2021 ·npj Materials Degradation ·(unknown), Philippe Dillmann, Stéṕhane Gin, Delphine Neff, (unknown), (unknown), I. Monnet, Emmanuel Gardès, Mandana Saheb, Eddy Foy, Nicolas Nuns, (unknown), James J. Dynes, Nicolas Michau, Christelle Martin	4
10	EGFR Exon 20 Insertion in Metastatic Non-Small-Cell Lung Cancer: Survival and Clinical Efficacy of EGFR Tyrosine-Kinase Inhibitor and Chemotherapy 2021 ·Cancers ·(unknown), (unknown), Karen Leroy, I. Monnet, Solenn Brosseau, Nathalie Théou–Anton, Marie-Ange Massiani, S. Friard, Boris Duchemann, Elizabeth Fabre, Etienne Giroux‐Leprieur, Jacques Cadranel, Marie Wislez	14
11	Multicenter phase II trial of nintedanib plus docetaxel in second-line treatment in advanced non-squamous non-small cell lung cancer patients refractory to first-line platin-based chemotherapy (REFRACT GFPC 02–15 study) 2021 ·Lung Cancer ·J.B. Auliac, I. Monnet, (unknown), Laurent Greillier, Margaux Geier, L. Falchero, G. Le Garff, R. Lamy, Florian Guisier, Charles Ricordel, C. Chouaïd, A. Vergnenègre	3
12	Ionization-induced annealing in silicon upon dual-beam irradiation 2020 ·Journal of Materials Science ·L. Thomé, G. Gutierrez, I. Monnet, F. Garrido, A. Debelle	15
13	Durable responses to immunotherapy of non-small cell lung cancers harboring MET exon-14–skipping mutation: A series of 6 cases 2020 ·Lung Cancer ·(unknown), Jean‐Baptiste Assié, I. Monnet, Marie-Ange Massiani, (unknown), S. Friard, (unknown), Anne-Cécile Métivier, C. Chouaïd, L. Zemoura, Élisabeth Longchampt, Céline Callens, Samia Melaabi, Louis‐Jean Couderc, H. Doubre	39
14	Health-Related Quality of Life Impact from Adding Bevacizumab to Cisplatin-Pemetrexed in Malignant Pleural Mesothelioma in the MAPS IFCT-GFPC-0701 Phase III Trial 2019 ·Clinical Cancer Research ·Guillaume Eberst, Amélie Anota, Arnaud Scherpereel, Julien Mazières, J. Margery, Laurent Greillier, Clarisse Audigier-Valette, Denis Moro‐Sibilot, Olivier Molinier, H. Léna, F. Rivière, I. Monnet, V. Gounant, Henri Janicot, Radj Gervais, (unknown), (unknown), Franck Morin, Gérard Zalcman, Virginie Westeel	15
15	Safety of combined PD‐1 pathway inhibition and radiation therapy for non‐small‐cell lung cancer: A multicentric retrospective study from the GFPC 2018 ·Cancer Medicine ·Paul Lesueur, Alexandre Escande, Juliette Thariat, (unknown), I. Monnet, Alexis B. Cortot, D. Lerouge, S. Danhier, Pascal Dô, Catherine Dubos‐Arvis, C. Chouaïd, Radj Gervais	36
16	Second or 3rd line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Updated results of the IFCT-1501 MAPS2 randomized phase 2 trial 2017 ·Annals of Oncology ·Gérard Zalcman, Julien Mazières, Laurent Greillier, (unknown), (unknown), Olivier Bylicki, I. Monnet, R. Corre, Clarisse Audigier-Valette, M. Locatelli-Sanchez, Olivier Molinier, Luc Thiberville, T. Urban, David Planchard, Catherine Ligeza‐Poisson, Elodie Amour, Franck Morin, Denis Moro‐Sibilot, Arnaud Scherpereel	12
17	Thermal, mechanical and fluid flow aspects of the high power beam dump for FRIB 2016 ·Nuclear Instruments and Methods in Physics Research Section B Beam Interactions with Materials and Atoms ·(unknown), (unknown), (unknown), (unknown), Carl J. Boehlert, T. Burgess, (unknown), Catherine Colin, (unknown), (unknown), (unknown), Van Graves, C. Grygiel, (unknown), W. Mittig, I. Monnet, Harshkumar Patel, Frédérique Pellemoine, R. M. Ronningen, M. Schein	8
18	Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort 2015 ·Annals of Oncology ·Julien Mazières, Fabrice Barlési, Thomas Filleron, Benjamin Besse, I. Monnet, Michèle Beau‐Faller, Solange Peters, Éric Dansin, Martin Früh, Miklos Pless, Rafael Rosell, Marie Wislez, P. Fournel, Virginie Westeel, Federico Cappuzzo, Alexis B. Cortot, Denis Moro‐Sibilot, Julie Milia, Oliver Gautschi	219
19	Pulmonary Carcinoid Tumors and Asbestos Exposure 2012 ·The Annals of Occupational Hygiene ·Bénédicte Clin, Pascal Andujar, (unknown), (unknown), Françoise Le Pimpec‐Barthes, (unknown), Claire Danel, Françoise Galateau-Sallé, Bruno Housset, (unknown), M. Matrat, I. Monnet, Marc Riquet, Jean‐Claude Pairon	4
20	Randomized, Phase III Study of Gemcitabine or Erlotinib Maintenance Therapy Versus Observation, With Predefined Second-Line Treatment, After Cisplatin-Gemcitabine Induction Chemotherapy in Advanced Non–Small-Cell Lung Cancer 2012 ·Journal of Clinical Oncology ·M. Pérol, C. Chouaïd, David Pérol, Fabrice Barlési, Radj Gervais, Virginie Westeel, Jacky Créquit, H. Léna, A. Vergnenègre, Gérard Zalcman, I. Monnet, H. Le Caer, P. Fournel, L. Falchero, M. Poudenx, F. Vaylet, Céline Ségura‐Ferlay, Mojgan Devouassoux‐Shisheboran, Miquel Tarón, B. Milleron	166

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact